RxDoctor Payments Data

Carroll Odem, MD

Internal Medicine · Acworth, GANPI 1144224957

Payments from drug & device makers

$2,323in general payments, 2019–2025

Across 88 payments — averaging $26.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alpha Cognition USA, Inc.$748
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$748
  • Teva Pharmaceuticals USA, Inc.$347
  • Redhill Biopharma Inc.$93
  • Almatica Pharma LLC$54
  • Kaleo, Inc.$53
  • plus $281 from 12 others

What the payments were for

  • Food & beverage$2,323100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,323 in reported general payments places this provider in the 75th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$345,120
Medicare patients
760
Services billed
2,989

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban863$249,510
AustedoDeutetrabenazine21$74,100
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$30,666
LinzessLinaclotide46$25,169
FarxigaDapagliflozin Propanediol76$22,336
TrulicityDulaglutide34$20,653
XareltoRivaroxaban76$20,487
MyrbetriqMirabegron85$19,285
MounjaroTirzepatide17$16,089
Sevelamer Carbonate58$15,687
JardianceEmpagliflozin58$15,574
SantylCollagenase Clostridium Hist.17$13,761
VeltassaPatiromer Calcium Sorbitex16$13,297
Atorvastatin Calcium763$12,814
CreonLipase/Protease/Amylase12$12,394

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$249,510863 claims
Teva Pharmaceuticals USA, Inc.Austedo$347$74,10021 claims
AbbVieLinzess, Creon$15$37,56358 claims
Redhill Biopharma Inc.Movantik$93$7,29338 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Acworth

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →